Discounted Cash Flow
Evolent Health, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $254.2m | $-159.7m | $-51.0m | -62.8% | $-3.55 |
| 2017 | $434.9m (71.1%) | $-60.7m (62.0%) | $-55.8m (-9.3%) | -13.9% (77.8%) | $-0.94 (73.5%) |
| 2018 | $627.1m (44.2%) | $-52.7m (13.2%) | $-60.2m (-7.9%) | -8.4% (39.8%) | $-0.68 (27.7%) |
| 2019 | $846.4m (35.0%) | $-302.0m (-473.5%) | $-78.2m (-29.9%) | -35.7% (-324.9%) | $-3.67 (-439.7%) |
| 2020 | $1.0b (20.8%) | $-334.2m (-10.7%) | $-45.7m (41.5%) | -32.7% (8.4%) | $-3.94 (-7.4%) |
| 2021 | $908.0m (-11.2%) | $-37.6m (88.8%) | $13.8m (130.1%) | -4.1% (87.3%) | $-0.44 (88.8%) |
| 2022 | $1.4b (48.9%) | $-19.2m (49.0%) | $-49.9m (-462.6%) | -1.4% (65.8%) | $-0.20 (54.5%) |
| 2023 | $2.0b (45.3%) | $-142.3m (-642.3%) | $113.8m (328.1%) | -7.2% (-411.0%) | $-1.28 (-540.0%) |
| 2024 | $2.6b (30.1%) | $-93.5m (34.3%) | $-6.1m (-105.4%) | -3.7% (49.5%) | $-0.81 (36.7%) |
| 2025 | $1.9b (-26.6%) | $-579.4m (-520.0%) | $4.8m (177.6%) | -30.9% (-744.2%) | $-5.07 (-525.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.